Related by context. All words. (Click for frequent words.) 81 midstage clinical trial 66 midstage trials 65 experimental hepatitis C 64 midstage clinical 64 Tocosol Paclitaxel 64 experimental lupus 64 rolofylline 64 midstage studies 63 midstage clinical trials 63 phase IIb trial 62 iniparib 62 Telcyta 62 Corlux 62 MyVax 62 ocrelizumab 61 efficacy endpoint 61 Ocrelizumab 61 phase IIb study 61 Phase IIa trial 61 ProSavin 61 Phase 2a trial 61 Recentin 61 motesanib 60 Levadex 60 Phase III trials 60 Phase Ib study 60 NV1FGF 60 Fablyn 60 bicifadine 60 Zybrestat 60 clinical trial 59 Phase IIb trial 59 GRN# 59 brentuximab 59 drug PTK ZK 59 BZL# 59 SUCCEED trial 59 rEV# 59 Tolamba 59 tofacitinib 59 phase IIb clinical 59 daclizumab 59 mipomersen 59 Phase 2b study 59 PTK ZK 59 Canvaxin 59 trastuzumab DM1 58 cannabinor 58 Ziopharm 58 ImClone Erbitux 58 PRT# 58 figitumumab 58 phase IIa 58 Xinlay 58 Nuvion 58 PEG PAL 58 Acadia Pharmaceuticals 58 ruxolitinib 58 Phase IIb trials 58 INCB# [001] 58 Ixempra 58 apremilast 58 Mipomersen 58 phase IIb 58 BAY #-# 58 Phase 2b trial 58 GALNS 58 cetuximab Erbitux 58 dexanabinol 58 Oxigene 58 pertuzumab 57 ruboxistaurin 57 Nasdaq OPTR 57 Amgen Vectibix 57 OvaRex 57 Relovair 57 elotuzumab 57 Oncogenex 57 RSR# 57 Fodosine 57 KRN# 57 ustekinumab 57 rALLy trial 57 orBec 57 Preos 57 tremelimumab 57 picoplatin 57 prostate cancer antigen prostatic 57 blood clot preventer 57 Xyotax 57 glufosfamide 57 lumiliximab 57 Bristol Myers Squibb Sustiva 57 velafermin 57 Omapro 57 clazosentan 57 cediranib 57 BRAF inhibitor 57 Phase IIb clinical trials 57 axitinib 57 Pimavanserin 57 dirucotide 57 Synavive 57 aflibercept 57 enzastaurin 57 Nexavar sorafenib 57 Reverset 57 drug crizotinib 57 oral ridaforolimus 57 Viramidine 57 mertansine 57 bosutinib 57 lintuzumab 57 Aflibercept 57 bardoxolone methyl 56 darusentan 56 arzoxifene 56 Neuvenge 56 maribavir 56 Panzem 56 incyclinide 56 registrational trial 56 Troxatyl 56 semagacestat 56 Phenoptin 56 Darusentan 56 Abiraterone acetate 56 Iressa lung cancer 56 Golimumab 56 phase 2a 56 atrasentan 56 alvespimycin 56 Prosaptide 56 otelixizumab 56 deforolimus 56 mapatumumab 56 JAK inhibitor 56 personalized immunotherapy 56 riociguat 56 T DM1 56 VitiGam 56 Orexigen Therapeutics Inc. 56 Asentar 56 clinical pharmacology studies 56 Heplisav 56 DPX Survivac 56 Sprycel 56 AEGR 56 Desmoteplase 56 Diamyd ® 56 Orexigen Therapeutics Inc 56 GVAX 56 Phase IIa clinical 56 TroVax 56 Itopride 56 dacetuzumab 56 Phase IIb 56 Qnexa 56 phase Ib 56 Cerovive 56 LAF# 56 immunotherapeutic vaccine 56 NP2 Enkephalin 56 ATL# [001] 56 Triolex 56 pazopanib 56 Xenoport Inc. 56 anidulafungin 56 Gattex 56 GLPG# 56 darapladib 56 tasisulam 56 mTOR inhibitor 55 Telintra 55 Galida 55 Vitaxin 55 Kynapid 55 motavizumab 55 drug figitumumab 55 PS# [001] 55 oral methylnaltrexone 55 Dendreon Provenge 55 TBC# 55 CDP# 55 NASDAQ REGN 55 Phase Ib clinical 55 tanespimycin 55 Personalized Immunotherapy 55 Provenge prostate cancer 55 neratinib 55 Rezular 55 GSK# [002] 55 Orexigen Contrave 55 Phase 2a clinical 55 exenatide LAR 55 IRX 2 55 PF # [002] 55 Vernakalant 55 TACI Ig 55 Mycograb 55 Promacta 55 baminercept 55 liprotamase 55 pomalidomide 55 PROSTVAC TM 55 antibody MAb 55 Vertex Pharma 55 Phase III clinical 55 IIa trial 55 Antegren 55 compound INCB# 55 Nasdaq ACHN 55 investigational therapies 55 aleglitazar 55 Fibrillex 55 Ostarine 55 Phase IIb clinical 55 Archexin 55 Menerba 55 olaparib 55 HuMax CD# 55 NASDAQ PCYC 55 Muraglitazar 55 ABX EGF 55 teduglutide 55 eritoran 55 iclaprim 55 tasocitinib 55 oral prodrug 55 Xenoport 55 CRLX# 55 Tarceva TM 55 Benlysta belimumab 55 QNEXA 55 omacetaxine mepesuccinate 55 Factor VIIa 55 Theratope 55 eniluracil 55 Fusilev 55 telaprevir 55 teriflunomide 55 RSD# oral 55 Bydureon 54 phase IIa clinical 54 MYDICAR 54 preclinical efficacy 54 Schering Plough Corp SGP.N 54 ABSORB trial 54 Crizotinib 54 Celgene Revlimid 54 TG# [003] 54 MyVax personalized immunotherapy 54 Pegintron 54 ponatinib 54 INCB# [002] 54 cangrelor 54 investigational monoclonal antibody 54 investigational compound 54 clinical trials 54 CR# vcMMAE 54 reslizumab 54 TOCOSOL Camptothecin 54 Corcept Therapeutics 54 Vivus Qnexa 54 taranabant 54 Phase 1b trial 54 tasimelteon 54 LymphoStat B 54 lomitapide 54 Phase #b/#a trial 54 Sutent sunitinib 54 pradefovir 54 atacicept 54 Oglemilast 54 aclidinium 54 tolevamer 54 Treanda 54 teplizumab 54 ICA # 54 Campath alemtuzumab 54 Velcade bortezomib 54 Flutiform 54 Nymox Pharmaceutical 54 gefitinib Iressa 54 lorcaserin 54 CoFactor 54 Cimzia TM 54 bapineuzumab 54 drug Treanda 54 VA# [002] 54 dexpramipexole 54 Alzhemed 54 HuMax EGFr 54 Fx #A 54 regorafenib 54 Curagen 54 pharmacokinetic PK study 54 Onrigin 54 Phase 2b clinical 54 preclinically 54 Vivus Inc 54 Aryx 54 ThGRF 54 Acapodene 54 azilsartan medoxomil 54 lymphoma CTCL 54 PEG SN# 54 nalbuphine ER 54 Insegia 54 Prestara 54 Stelara 54 virus HCV protease inhibitor 54 sunitinib 54 AZD# 54 TSX COM 54 drug Recentin 54 Ereska 54 obatoclax 54 LymphoStat B TM 54 alemtuzumab Campath 54 sitaxsentan 54 OMAPRO 54 Vertex hepatitis C 54 Daniel Junius 54 dalbavancin 54 Annamycin 54 PTK# 54 Sulonex 54 rNAPc2 54 zalutumumab 54 Medivation Inc 54 Northera 54 histone deacetylase HDAC inhibitor 54 VEGF Trap 54 davalintide 54 investigational humanized monoclonal antibody 54 huC# DM4 53 Hedgehog antagonist 53 Arcalyst 53 Tarceva erlotinib 53 JAK2 inhibitor 53 Orexigen Therapeutics 53 Phase Ib 53 ATHX 53 evaluating tivozanib 53 rindopepimut 53 Firazyr 53 Entereg 53 torezolid phosphate 53 vinflunine 53 Alocrest 53 noninferiority 53 Adentri 53 Phase 2b clinical trials 53 placebo controlled clinical 53 denufosol 53 MK #A [001] 53 selective androgen receptor modulator 53 TELINTRA 53 pain palliation 53 GRN#L 53 Pirfenidone 53 Phase #b/#a 53 Allovectin 7 53 IND submission 53 PDE4 inhibitor 53 CINTREDEKIN BESUDOTOX 53 erlotinib Tarceva 53 vismodegib 53 PSMA ADC 53 trodusquemine 53 tecarfarin 53 NSABP C 53 vidofludimus 53 Elocalcitol 53 hematological indications 53 Phase 2a 53 Folotyn 53 TELCYTA 53 PROMACTA 53 Zolinza 53 almorexant 53 CA4P 53 Amigal 53 antisense drug 53 Merck KGaA Erbitux 53 Zactima 53 ganetespib 53 Pulminiq 53 vernakalant 53 Amrubicin 53 vandetanib 53 Ceflatonin 53 solanezumab 53 Phase #/#a trial 53 blood thinner prasugrel 53 Dapagliflozin 53 tanezumab 53 MAXY alpha 53 QLT# 53 Dendreon Corp 53 ALN VSP Phase 53 eltrombopag 53 anacetrapib 53 seliciclib CYC# 53 LymphoStat B belimumab 53 rALLy clinical trial 53 TRV# [001] 53 blinatumomab 53 Aplidin 53 gaboxadol 53 Contrave 53 Tykerb lapatinib 53 initiate Phase IIb 53 adjuvant colon cancer 53 Phase 1b 53 Juvista 53 Proxinium TM 53 Vion Pharmaceuticals 53 farletuzumab 53 Urocidin 53 investigational hepatitis C 53 IMA# 53 Allovectin 7 ® 53 TOLAMBA 53 adalimumab Humira 53 Alimta pemetrexed 53 JAK3 inhibitor 53 AQ4N 53 Phase Ib clinical trials 53 EGS# 53 Phase #/#a 53 elagolix 53 denosumab 53 SRT# [003] 53 RGB # 53 Genentech Rituxan 53 viral kinetics 53 PEG Interferon lambda 53 primary endpoints 53 targeted radiotherapeutic 53 sorafenib tablets 53 GRNCM1 53 Evoltra TM 53 Trexima 53 Phase 1a clinical 53 vemurafenib 53 Affinitak 53 preclinical 53 Vibativ 53 Tasimelteon 53 Zalbin 53 Phase 2a clinical trials 53 Phase IIa 53 TPI ASM8 53 Varisolve 53 IMC #B 53 Amevive 53 Vertex telaprevir 53 maximally tolerated dose 53 Zensana 52 alvimopan 52 Onconase 52 MyVax R 52 ZOLINZA 52 Cloretazine 52 ISIS # 52 Aryplase 52 CTAP# Capsules 52 lintuzumab SGN 52 brivaracetam 52 PEARL SC 52 HuMax CD4 52 Avastin Tarceva 52 Vectibix 52 Solzira 52 PRECISE Trial 52 PSN# [002] 52 Tocosol 52 milatuzumab 52 forodesine 52 Azedra TM 52 Vorapaxar 52 Sudhir Agrawal D.Phil 52 primary endpoint 52 Zarnestra 52 Pruvel 52 budesonide foam 52 Immunogen 52 Androxal TM 52 Atherogenics 52 crizotinib 52 Laquinimod 52 panitumumab Vectibix 52 Acetavance 52 OZURDEX ® 52 hepatitis B vaccine Heplisav 52 sunitinib Sutent 52 bifeprunox 52 diet pill Qnexa 52 Arena lorcaserin 52 Memryte 52 betrixaban 52 alogliptin 52 OvaRex ® MAb 52 Zenvia Phase III 52 Zometa zoledronic acid 52 BrachySil 52 panitumumab 52 Cinquil 52 Lorcaserin 52 VIAject 52 rhThrombin 52 EndoTAGTM 1 52 oxymorphone ER 52 StaphVAX 52 Revlimid 52 Aegerion Pharmaceuticals Inc. 52 ASA# 52 dose cohort 52 elvitegravir 52 Seattle Genetics SGEN 52 TASKi3 52 active comparator 52 peginesatide 52 non nucleoside inhibitor 52 Onyx Pharmaceuticals 52 taxane refractory 52 OHR/AVR# 52 Nasulin 52 ALN PCS 52 Virulizin ® 52 preclinical studies 52 Adventrx 52 Avastin colon cancer 52 CETP inhibitor 52 enoximone 52 Phase III 52 NASDAQ OREX 52 BRIM3 52 Atrasentan 52 CRx 52 hematological cancers 52 opioid induced bowel dysfunction 52 Orathecin 52 lorvotuzumab mertansine 52 Trofex TM 52 Zemplar Capsules 52 Urocortin 2 52 Azedra 52 Romiplostim 52 GVAX AML 52 Carfilzomib 52 mTOR inhibition 52 Omacetaxine 52 Omigard 52 DPP4 52 HGS# 52 Zerenex 52 Milnacipran 52 proteasome inhibitor 52 TNFerade 52 TSX LOR 52 Hematide 52 Vectibix panitumumab 52 Krystexxa 52 Phase III clinical trials 52 angiogenesis inhibitor 52 pegylated interferon peg IFN 52 anti CD3 antibody 52 blood thinner Xarelto 52 LibiGel ® 52 Alfimeprase 52 IMC A# 52 Maximum Tolerated Dose 52 Afrezza 52 MAP Pharma 52 confirmatory Phase III 52 Taranabant 52 Zelrix 52 Votrient 52 Arzerra 52 PXD# 52 CIMZIA TM certolizumab pegol 52 Troxatyl TM 52 CCX# 52 ASONEP ™ 52 CIMZIA TM 52 DXL# 52 Contrave# 52 Civacir 52 Arranon 52 SYMMETRY trial 52 Zenvia ™ 52 ixabepilone 52 MGd 52 AVE# 52 Hedgehog Pathway Inhibitor 52 Alzhemed TM 52 UCB Cimzia 52 QNEXA ® 52 Panzem R 52 ELACYT 52 Erbitux cetuximab 52 Phase IIIb clinical 52 Adlea 52 perifosine 52 Safinamide 52 Synta Pharmaceuticals 52 ASSERT trial 52 crizotinib PF # 52 Iluvien ® 52 CytoFabTM 52 cabozantinib 52 Tesofensine 52 RLY# 52 canagliflozin 52 lixisenatide 52 Amylin AMLN 52 VitiGam TM 52 candidates Dyloject TM 52 GLP toxicology studies 52 Oncologic Drugs Advisory 52 Provenge sipuleucel T 52 Novartis Afinitor 52 Zemiva TM 52 SMT C# 52 Empatic 52 Provenge Dendreon 52 Ozarelix 52 BRIM2 52 elesclomol 52 abiraterone 52 Pivotal Clinical Trial 52 HGS ETR1 52 avanafil 52 diabetic neuropathic pain 52 serum uric acid sUA 52 A3 adenosine receptor 52 varespladib 52 registrational 52 ozarelix 52 μg dose 52 zanolimumab 52 ARRY 52 taspoglutide 52 FDA Oncologic Drugs 52 TOCOSOL Paclitaxel 52 Onyx Pharmaceuticals ONXX 52 Vicriviroc 52 levosimendan 51 Xcytrin R 51 Unit Dose Budesonide 51 Aurexis 51 STRIDE PD 51 alfimeprase 51 desvenlafaxine succinate 51 XmAb# 51 VRTX 51 tezampanel 51 AIMM trial 51 SU# [003] 51 oral deforolimus 51 Vandetanib 51 JZP 6 51 Study GL# 51 Advexin 51 HspE7 51 DPP4 inhibitor 51 pimavanserin 51 Ketotransdel 51 peg interferon 51 EVIZON 51 secondary efficacy endpoints 51 Lorqess 51 Cimzia 51 S/GSK# 51 CRD5 51 CB2 selective receptor agonist 51 Phase Ib II 51 OncoVEX GM CSF 51 SAR# [004] 51 Ambrisentan 51 lurasidone 51 E2F Decoy 51 MEND CABG 51 macitentan 51 Nicole Onetto MD 51 Elan Tysabri 51 investigational drug 51 NexACT 51 viral kinetic 51 Xibrom QD 51 rALLy 51 Ampligen 51 CRMD# 51 Femara letrozole 51 volociximab 51 Roche Actemra 51 Enbrel etanercept 51 Bronchitol 51 Genentech Herceptin 51 Dasatinib 51 Mepact 51 samalizumab 51 APTIVUS R 51 Degludec 51 MNTX 51 Lung Rx 51 pramlintide 51 Veronate 51 aerosolized KL4 surfactant 51 Genzyme Isis 51 Potiga 51 Targretin 51 cancer neuroendocrine tumor 51 Dimebon 51 RANK Ligand inhibitor 51 Bicifadine 51 fampridine SR 51 multicenter Phase II 51 refractory APL 51 XL# SAR# 51 Cogane 51 Lu AA# 51 methylnaltrexone 51 BNC# 51 OvaRex R 51 Sym# 51 zotarolimus eluting stent 51 LibiGel Phase III 51 ACZ# 51 FTY# fingolimod 51 Marqibo 51 RE COVER 51 Phase 1b clinical 51 telcagepant 51 GGF2 51 TroVax ® 51 Tarvacin TM 51 Bifeprunox 51 Horizant 51 Phase Ia 51 MAP# 51 vaccine Stimuvax 51 INCB# [003] 51 Gemin X 51 Torisel 51 Eliquis 51 Serdaxin 51 Technosphere Insulin 51 Pfizer Sutent 51 noninfectious uveitis 51 RhuDex 51 FTY# 51 Quinamed 51 Provecta 51 Dose Ranging Study 51 PRX # 51 pediatric acute lymphoblastic 51 Regeneron Pharma 51 senicapoc 51 ocular formulation 51 SIMPADICO trial 51 Tekamlo 51 Diamyd R 51 Daclizumab 51 MabThera rituximab 51 BrachySil TM 51 BCX# 51 Bezielle 51 Gleevec imatinib mesylate 51 MEND CABG II 51 elacytarabine 51 Elagolix 51 taribavirin 51 Alequel 51 Bristol Myers Squibb BMY.N 51 SinuNase 51 Onyx Pharma 51 protein kinase inhibitor 51 OncoVEX 51 NASDAQ ANDS 51 randomized Phase IIb 51 pharmacokinetic PK 51 DU #b 51 MS relapses 51 iloperidone 51 Telbivudine 51 efaproxiral 51 Idenix Pharmaceuticals 51 Revlimid lenalidomide 51 Gleevec imatinib 51 Raptiva efalizumab 51 Metabolic Drugs Advisory 51 Tasigna nilotinib 51 MGN# 51 Pegasys plus Copegus 51 RezularTM 51 Lorianne Masuoka MD 51 rivaroxaban Xarelto 51 EOquin TM 51 TNF alpha inhibitor 51 Cardio Vascu Grow 51 ToGA 51 non inferiority 51 cortical stimulation therapy 51 tafamidis 51 myoblast therapy 51 ostarine 51 HCV RESPOND 2 51 Phase #b/#a clinical 51 StaphVax 51 AZD# TC 51 T Pred 51 efficacy tolerability 51 inhaled iloprost 51 DCVax 51 SCH # 51 immunological diseases 51 MAGE A3 ASCI 51 ataluren 51 ONXX 51 depsipeptide 51 Certriad 51 ranibizumab 51 Dacogen injection 51 PANVAC VF 51 tolerability profiles 51 CBLC# 51 Reolysin 51 avosentan 51 pharmacodynamic effects 51 Iloperidone 51 YONDELIS 51 REGN# 51 relapsed multiple myeloma 51 Denosumab 51 blood thinner Brilinta 51 pivotal Phase III 51 Affymax AFFY 51 Nexavar 51 integrase inhibitor 51 Retaane 51 cathepsin K inhibitor 51 investigational compounds 51 investigational oral hepatitis C 51 Replagal 51 edoxaban 51 dasatinib 51 Trofex 51 Rezonic 51 Liraglutide 51 Plicera 51 aclidinium bromide 51 Apoptone 51 Phase IIIb study 51 pramlintide metreleptin 51 investigational antiplatelet agent 51 lapatinib Tykerb 51 Tykerb 51 SinuNase TM 51 DAC HYP 51 assessing T DM1 51 Betaferon multiple sclerosis 51 AVASTIN 51 Crestor rosuvastatin 51 Octreotide 51 investigational immunotherapy 51 CAMPATH 51 BLA filing 51 OncoVex 51 LY# [002] 51 pharmacokinetic equivalence 51 dose escalation trial 51 VIR# 51 Xelox 51 Taxotere chemotherapy 50 ImmunoCellular Therapeutics 50 ACV1 50 visilizumab 50 Fibrillex TM 50 dose escalation phase 50 class mGluR5 inhibitor 50 pivotal bioequivalence 50 GRNVAC1 50 squalamine 50 Rituxan rituximab 50 telavancin 50 sorafenib Nexavar 50 Sebivo 50 Panzem R NCD 50 HQK 50 Pertuzumab 50 HGS ETR2 50 PRIMO CABG 50 Zavesca 50 Gilenia 50 VEGF inhibitor 50 bevacizumab Avastin 50 primary efficacy endpoint 50 prospectively defined 50 omacetaxine 50 TKM ApoB 50 LEVADEX 50 Rebif ® 50 corticosteroid dexamethasone 50 Avastin adjuvant 50 ospemifene 50 GOUT 50 metaglidasen 50 Oral lyn 50 Q#IR 50 Velcade 50 therapeutic monoclonal antibody 50 belinostat 50 1mg dose 50 PREOS 50 advanced HER2 positive 50 Febuxostat 50 Phase IIa trials 50 Xgeva 50 clevidipine 50 afatinib 50 fostamatinib disodium 50 TLK# 50 Doxil ® 50 Clolar 50 fostamatinib 50 VADT 50 gepirone ER 50 R#/MEM # 50 galiximab 50 GAMMAGARD 50 Sparlon 50 fingolimod 50 Yondelis 50 ACAPODENE 50 HuLuc# 50 pirfenidone 50 Proxinium 50 valopicitabine 50 Campath ® 50 ENDEAVOR IV 50 vaccine Cervarix 50 dose escalation Phase 50 Oral NKTR 50 metastatic renal cell 50 Proellex TM 50 faropenem 50 Roche Holding AG ROG.VX 50 PLX# 50 Inspra 50 Board DSMB 50 phase Ib clinical 50 ENRICH trial 50 ALKS 50 Factor Xa inhibitor 50 mg/m2 cohort 50 investigational oral therapy 50 Ron Bentsur 50 EMPHASIS HF trial 50 Zoraxel 50 Xanafide 50 refractory chronic myeloid 50 Nanobody 50 oxypurinol 50 chronic myeloid leukemia CML 50 Phase 1b clinical trials 50 Combidex 50 phase IIIb 50 ipilimumab 50 Mozobil 50 alemtuzumab 50 bortezomib Velcade 50 Tyvaso 50 IIa clinical trial 50 FOLOTYN ® 50 Genz # 50 radezolid 50 intermittent dosing 50 danoprevir 50 DAVANAT 50 Vivecon 50 thalidomide Thalomid 50 Aclidinium 50 dapagliflozin 50 briakinumab 50 cobiprostone 50 custirsen 50 cetrorelix pamoate 50 Zyflo 50 Orexigen 50 tolerability 50 bendamustine 50 R sorafenib tablets 50 Neugene 50 refractory angina 50 TNF inhibitor